SynergyMed raised on Wefunder, and had a similar solution to the problem of cancer treatment. Their value cap was only 16M, which was much more appealing to me. Their approach was also to break into the Vet market first, to prove their technology. To generate revenue, and pote...

Question

Accepted Answer

Jesse, we looked into the vet cancer market. It is very limited for novel technologies based on our market research. DIPG is a very rare, terminal, pediatric brain cancer. A relative short FDA path. Pain management is also a expeditious path to revenue. We are planning a direct Nasdaq listing this year, so your investment will be liquid. Thanks for your consideration. Best

EMulate Therapeutics

Revolutionary Transformation of Medicine with BioElectromagnetic Technology

EMulate Therapeutics

Quick facts

Team profiles

Ask